Agenda-setting intelligence, analysis and advice for the global fashion community.
Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk’s Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.
Please sign in to ensure you can read our agenda-setting intelligence, analysis and advice. Or get in touch at support@businessoffashion.com if you experience difficulties.




